第1阶段,MEDI1341的随机试验:大脑脊髓液中自由的α-synuclein降低了>50%
Craig Shering1, Michael Pomfret2, Robert J Kubiak3
1Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Boston, MA 02210, USA.
Brain communications
|September 12, 2025
概括
针对α-synuclein的抗体MEDI1341在帕金森病患者中显示出良好的安全性和耐受性. 它有效地降低了脑脊液中的α-synuclein水平,支持了进一步的临床开发.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔法-同核素聚合是帕金森病病原体的核心.
- MEDI1341是一种新型单克隆抗体,旨在向病理性α-synuclein.
- 临床前数据表明MEDI1341可以减少α-synuclein的积累和传播.
研究的目的:
- 评估MEDI1341在健康参与者和患有帕金森病的人群中的安全性,耐受性,药理动力学和药理动力学.
- 评估MEDI1341对脑脊液 (CSF) 中的α-synuclein水平的剂量依赖性影响.
主要方法:
- 进行了两个1期,随机,双盲,安慰剂控制的研究:健康参与者的单个上升剂量 (SAD) 研究和帕金森病患者的多重上升剂量 (MAD) 研究.
- 参与者接受了MEDI1341或安慰剂的静脉注射.
- 评估了安全性,耐受性,药理动力学 (血清和CSF MEDI1341),药理动力学 (血和CSF中的总和自由α-synuclein) 和免疫性.
主要成果:
- 在这两项研究中,MEDI1341显示出良好的安全性和耐受性.
- 观察到血清度与剂量成比例增加,终端消除半衰期较长 (16.6-24.3天).
- 在CSF中观察到自由α-synuclein的显著减少,最高剂量的基线变化高达-59.0%,支持其作为帕金森病治疗药物的潜力.
结论:
- 梅迪1341具有良好的安全性,耐受性,药理动力学和药理动力学特征.
- 它是第一个针对α-synuclein的单克隆抗体,能够显著降低CSF中的自由α-synuclein.
- 这些发现支持MEDI1341对帕金森病的持续临床开发.
更多相关视频
06:22A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
Published on: September 3, 2021
4.0K
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
11.2K
相关概念视频
Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Parkinson's Disease: Treatment
995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
Clinical Trials
10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.2K
